No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
www.kringle-pharma.comNo one on the platform currently holds 4884.T.
No tracked institution reports a position in 4884.T as of their last filing.
No one on the platform has traded 4884.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | -9.8% | -31.2% | ||||
| Profit Margin % | -1268.8% | -727.2% | ||||
| Free Cash Flow Margin % | 0.0% | -402.1% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.1B | -8.6% | $-20.00 | $-20.00–$-20.00 | — | 1 |
| 2027 | $4.1B | +280.9% | $286.00 | $286.00–$286.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 4884.TKringle Pharma, Inc. | $440.00 | -2.22% | $3.6B | — |
| 2342.TTrans Genic Inc. | $250.00 | -1.96% | $4.2B | — |
| 2425.TCare Service Co.,Ltd. | $675.00 | +0.15% | $2.6B | — |
| 4438.TWelby Inc. | $246.00 | -1.20% | $2.1B | — |
| 4572.TCarna Biosciences, Inc. | $432.00 | +0.70% | $8.3B | — |
| 4591.TRibomic Inc. | $79.00 | -2.47% | $4.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
| 4596.TKubota Pharmaceutical Holdings Co., Ltd. | $67.00 | +1.52% | $9.4B | — |